Patient Access | TRYNGOLZA™ (olezarsen) Injection

We understand the challenges your patients face and are committed to simplifying the process to get TRYNGOLZA for them.

Ionis Every Step™ services include the following:

Insurance assistance

An Ionis Every Step Case Manager will work with you and your staff to navigate the insurance approval process. The Case Manager will complete a benefit verification, identify plan-specific requirements, and provide prior authorization, appeal, and reauthorization support.*

Financial assistance

Commercially insured patients may pay as little as $0 out of pocket per fill.^† Ionis Every Step will assess each patient’s eligibility for our financial support programs and provide them with information on the appropriate programs if their insurance is not covering TRYNGOLZA.^‡

*Insurance approval is not guaranteed. Ionis Every Step offers financial assistance programs for patients who are uninsured or denied coverage for their Ionis medication.
^†Eligibility restrictions: This program is not available to individuals who use any state or federal government-funded health care program to cover a portion of medication costs, such as Medicare, Medicaid, TRICARE, Department of Defense, or Veterans Administration, or any other state or federal government-funded healthcare program.
^‡Subject to program terms, conditions, and limits.

For more information about Ionis Every Step, call 1-844-789-8744 (Monday to Friday, 8 AM to 8 PM ET)

Learn about patient support

Important safety information

CONTRAINDICATIONS

TRYNGOLZA is contraindicated in patients with a history of serious hypersensitivity to TRYNGOLZA or any of the excipients in TRYNGOLZA. Hypersensitivity reactions requiring medical treatment have occurred.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions (including symptoms of bronchospasm, diffuse erythema, facial swelling, urticaria, chills, and myalgias) have been reported in patients treated with TRYNGOLZA. Advise patients on the signs and symptoms of hypersensitivity reactions and instruct patients to promptly seek medical attention and discontinue use of TRYNGOLZA if hypersensitivity reactions occur.

ADVERSE REACTIONS

Most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and >3% higher frequency than placebo) were injection site reactions, decreased platelet count, and arthralgia.

Important safety information

CONTRAINDICATIONS

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

ADVERSE REACTIONS

Most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and >3% higher frequency than placebo) were injection site reactions, decreased platelet count, and arthralgia.

Access and support

Ionis Every Step™ services include the following:

Indication

Important safety information

CONTRAINDICATIONS

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

ADVERSE REACTIONS